Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tomaras

Showing results (201-210 of 525) with videos related to

Pageof 53
Sort By:
The Journal of Infectious Diseases|November 17, 2005
Safety and immunogenicity of an HIV-1 recombinant canarypox vaccine in newborns and infants of HIV-1-infected womenDaniel C Johnson, Elizabeth J McFarland, Petronella Muresan, et al.
Journal of Virology|September 16, 2011
Differential reactivity of germ line allelic variants of a broadly neutralizing HIV-1 antibody to a gp41 fusion intermediate conformationS Munir Alam, Hua-Xin Liao, S Moses Dennison, et al.
Cytometry. Part a : the Journal of the International Society for Analytical Cytology|July 8, 2011
High-throughput quantitative analysis of HIV-1 and SIV-specific ADCC-mediating antibody responsesJustin Pollara, Lydia Hart, Faraha Brewer, et al.
Scientific Reports|July 17, 2019
HLA class II-Restricted CD8+ T cells in HIV-1 Virus ControllersTinashe E Nyanhete, Alyse L Frisbee, Todd Bradley, et al.
Human Vaccines & Immunotherapeutics|July 4, 2013
Vaccination with Vaxfectin(®) adjuvanted SIV DNA induces long-lasting humoral immune responses able to reduce SIVmac251 ViremiaViraj Kulkarni, Margherita Rosati, Antonio Valentin, et al.
Journal of Virology|May 6, 2011
An HIV-1 gp120 envelope human monoclonal antibody that recognizes a C1 conformational epitope mediates potent antibody-dependent cellular cytotoxicity (ADCC) activity and defines a common ADCC epitope in human HIV-1 serumGuido Ferrari, Justin Pollara, Daniel Kozink, et al.
Journal of Virology|November 3, 2021
Selection of HIV Envelope Strains for Standardized Assessments of Vaccine-Elicited Antibody-Dependent Cellular Cytotoxicity-Mediating AntibodiesDieter Mielke, Sherry Stanfield-Oakley, Bhavesh Borate, et al.
The Journal of Infectious Diseases|September 24, 2011
Timing of plasmid cytokine (IL-2/Ig) administration affects HIV-1 vaccine immunogenicity in HIV-seronegative subjectsLindsey R Baden, William A Blattner, Cecilia Morgan, et al.
Cell Reports|March 2, 2022
Structure-guided changes at the V2 apex of HIV-1 clade C trimer enhance elicitation of autologous neutralizing and broad V1V2-scaffold antibodiesAnusmita Sahoo, Edgar A Hodge, Celia C LaBranche, et al.
Frontiers in Immunology|September 10, 2021
Validation of a Triplex Pharmacokinetic Assay for Simultaneous Quantitation of HIV-1 Broadly Neutralizing Antibodies PGT121, PGDM1400, and VRC07-523-LSMartina S Wesley, Kelvin T Chiong, Kelly E Seaton, et al.
Pageof 53

Showing results (201-210 of 525) with videos related to

Sort By:
Pageof 53
The Journal of Infectious Diseases|November 17, 2005
Safety and immunogenicity of an HIV-1 recombinant canarypox vaccine in newborns and infants of HIV-1-infected womenDaniel C Johnson, Elizabeth J McFarland, Petronella Muresan, et al.
Journal of Virology|September 16, 2011
Differential reactivity of germ line allelic variants of a broadly neutralizing HIV-1 antibody to a gp41 fusion intermediate conformationS Munir Alam, Hua-Xin Liao, S Moses Dennison, et al.
Cytometry. Part a : the Journal of the International Society for Analytical Cytology|July 8, 2011
High-throughput quantitative analysis of HIV-1 and SIV-specific ADCC-mediating antibody responsesJustin Pollara, Lydia Hart, Faraha Brewer, et al.
Scientific Reports|July 17, 2019
HLA class II-Restricted CD8+ T cells in HIV-1 Virus ControllersTinashe E Nyanhete, Alyse L Frisbee, Todd Bradley, et al.
Human Vaccines & Immunotherapeutics|July 4, 2013
Vaccination with Vaxfectin(®) adjuvanted SIV DNA induces long-lasting humoral immune responses able to reduce SIVmac251 ViremiaViraj Kulkarni, Margherita Rosati, Antonio Valentin, et al.
Journal of Virology|May 6, 2011
An HIV-1 gp120 envelope human monoclonal antibody that recognizes a C1 conformational epitope mediates potent antibody-dependent cellular cytotoxicity (ADCC) activity and defines a common ADCC epitope in human HIV-1 serumGuido Ferrari, Justin Pollara, Daniel Kozink, et al.
Journal of Virology|November 3, 2021
Selection of HIV Envelope Strains for Standardized Assessments of Vaccine-Elicited Antibody-Dependent Cellular Cytotoxicity-Mediating AntibodiesDieter Mielke, Sherry Stanfield-Oakley, Bhavesh Borate, et al.
The Journal of Infectious Diseases|September 24, 2011
Timing of plasmid cytokine (IL-2/Ig) administration affects HIV-1 vaccine immunogenicity in HIV-seronegative subjectsLindsey R Baden, William A Blattner, Cecilia Morgan, et al.
Cell Reports|March 2, 2022
Structure-guided changes at the V2 apex of HIV-1 clade C trimer enhance elicitation of autologous neutralizing and broad V1V2-scaffold antibodiesAnusmita Sahoo, Edgar A Hodge, Celia C LaBranche, et al.
Frontiers in Immunology|September 10, 2021
Validation of a Triplex Pharmacokinetic Assay for Simultaneous Quantitation of HIV-1 Broadly Neutralizing Antibodies PGT121, PGDM1400, and VRC07-523-LSMartina S Wesley, Kelvin T Chiong, Kelly E Seaton, et al.
Pageof 53